Mr. Shkreli’s exit from the company followed one day after he was taken into custody by federal authorities on securities and fraud charges.
“We wish to thank Martin for helping us build Turing Pharmaceuticals into the dynamic research focused company it is today and we wish him the best in his future endeavors,” Turing Pharmaceuticals wrote in a statement.
Ron Tilles has been named interim CEO, according to the report.
More articles on executive moves:
MetroHealth System promotes Melissa Kline to CNO: 5 things to know
IU Health names 3 executive leaders: 10 things to know
Daniel Hilferty named chair of Blue Cross and Blue Shield Association of America
